Literature DB >> 16785190

Helicobacter pylori eradication in the healing of atrophic gastritis: a one-year prospective study.

Perttu E T Arkkila1, Kari Seppälä, Martti A Färkkilä, Lea Veijola, Pentti Sipponen.   

Abstract

OBJECTIVE: Whether gastric atrophy or intestinal metaplasia heals after successful treatment of Helicobacter pylori (H. pylori) infection is still a matter of controversy. The aim of this article was to clarify whether, after one year, H. pylori eradication is associated with healing in glandular atrophy and intestinal metaplasia in the corpus and antrum.
MATERIAL AND METHODS: Ninety-two H. pylori-positive peptic ulcer patients with atrophic gastritis (panatrophy, antral or corpus predominant) participated in the baseline study, 1-year prospective follow-up data being available from 76 patients. Mean age was 58+/-12.6 years (mean+/-SD) and the male/female ratio 2/1. The patients participated in an H. pylori eradication study in which they randomly received active eradication therapy. Endoscopy was performed before H. pylori eradication therapy and after 8 and 52 weeks, with specimens examined according to the Sydney system.
RESULTS: Of the 92 patients, 8 (9%) had panatrophy, 58 (63%) had antral- and 26 (28%) had corpus-predominant atrophic gastritis. After H. pylori eradication, the mean atrophy score declined in patients with antral-predominant atrophy from 1.5 (mean) to 0.7 (p<0.05), in corpus-predominant atrophy from 1.7 to 0.2 (p=NS) and in patients with panatrophy from 1.2 to 0.8 (p=NS). Atrophy healing was seen in 55% of antral-predominant atrophy patients who had successful H. pylori eradication. The mean antral atrophic score in one year declined in patients with duodenal ulcer (from 1.0 mean to 0.4) whereas it remained the same (1.3) in those with gastric ulcer (p<0.05).
CONCLUSIONS: Atrophy can diminish or even disappear, especially in the antrum, during a 1-year follow-up after eradication of infection. Atrophy progression seems milder in patients with duodenal ulcer than in patients with gastric ulcer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16785190     DOI: 10.1080/00365520500463175

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  7 in total

1.  Helicobacter pylori infection, atrophic gastritis, and risk of pancreatic cancer: A population-based cohort study in a large Japanese population: the JPHC Study.

Authors:  Mayo Hirabayashi; Manami Inoue; Norie Sawada; Eiko Saito; Sarah K Abe; Akihisa Hidaka; Motoki Iwasaki; Taiki Yamaji; Taichi Shimazu; Shoichiro Tsugane
Journal:  Sci Rep       Date:  2019-04-15       Impact factor: 4.379

2.  Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis.

Authors:  Hai-Ning Chen; Zhu Wang; Xiao Li; Zong-Guang Zhou
Journal:  Gastric Cancer       Date:  2015-01-22       Impact factor: 7.370

Review 3.  Histological changes of gastric mucosa after Helicobacter pylori eradication: a systematic review and meta-analysis.

Authors:  Yan-Jun Kong; Hong-Gang Yi; Jun-Cheng Dai; Mu-Xin Wei
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

Review 4.  Ghrelin and Helicobacter pylori infection.

Authors:  Hiroyuki Osawa
Journal:  World J Gastroenterol       Date:  2008-11-07       Impact factor: 5.742

Review 5.  Chronic gastritis.

Authors:  Pentti Sipponen; Heidi-Ingrid Maaroos
Journal:  Scand J Gastroenterol       Date:  2015-04-22       Impact factor: 2.423

6.  Gastritis - facts and doubts.

Authors:  Jacek Muszyński; Bartłomiej Ziółkowski; Paweł Kotarski; Adam Niegowski; Barbara Górnicka; Magdalena Bogdańska; Agnieszka Ehrmann-Jóśko; Magdalena Zemlak; Beata Młynarczyk-Bonikowska; Jolanta Siemińska
Journal:  Prz Gastroenterol       Date:  2016-09-08

7.  Endoscopic severe mucosal atrophy indicates the presence of gastric cancer after Helicobacter pylori eradication -analysis based on the Kyoto classification.

Authors:  Akiko Ohno; Jun Miyoshi; Atsushi Kato; Naohiko Miyamoto; Takahito Yatagai; Yu Hada; Mitsunori Kusuhara; Yoko Jimbo; Yosuke Ida; Kengo Tokunaga; Susumu Okamoto; Tadakazu Hisamatsu
Journal:  BMC Gastroenterol       Date:  2020-07-20       Impact factor: 3.067

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.